PTK7 and neoplasm: Damelin et al. developed a PTK7-targeted antibody–drug conjugate (PTK7–ADC), and treatment with PTK7–ADC depleted tumor-initiating cells and induced tumor regression in TNBC-patient-derived or TNBC-cell-line-derived xenografts [24].